Acute Lymphoblastic Leukemia (ALL)

Oncology
3
Pipeline Programs
4
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Design Therapeutics
1 program
1
CarfilzomibPhase 1
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
Erwinia Chrysanthemi asparaginasePhase 11 trial
Active Trials
NCT02647190Withdrawn0Est. Jun 2017
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
NavitoclaxPhase 15 trials
Active Trials
NCT04454658Active Not Recruiting21Est. Jan 2027
NCT04472598Completed252Est. Jan 2025
NCT04468984Active Not Recruiting330Est. Dec 2026
+2 more trials
Novartis
NovartisBASEL, Switzerland
1 program
CTL019N/A1 trial
Active Trials
NCT03601442Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AbbVieNavitoclax
AbbVieNavitoclax
AbbVieNavitoclax
AbbVieNavitoclax
AbbVieNavitoclax
AbbVieNavitoclax
AbbVieNavitoclax
Jazz PharmaceuticalsErwinia Chrysanthemi asparaginase

Clinical Trials (9)

Total enrollment: 961 patients across 9 trials

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Start: Sep 2020Est. completion: Jan 2025252 patients
Phase 3Completed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Start: Aug 2020Est. completion: Dec 2026330 patients
Phase 3Active Not Recruiting

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Start: Oct 2017Est. completion: Jan 2025191 patients
Phase 2Completed

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Start: Jun 2013Est. completion: Mar 201613 patients
Phase 2Terminated

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Start: Nov 2020Est. completion: Jan 202721 patients
Phase 1Active Not Recruiting

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Start: Nov 2019Est. completion: Dec 202685 patients
Phase 1Active Not Recruiting

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Start: Nov 2017Est. completion: Nov 202069 patients
Phase 1Completed
NCT02647190Jazz PharmaceuticalsErwinia Chrysanthemi asparaginase

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Start: Jan 2016Est. completion: Jun 20170
Phase 1Withdrawn

CTL019 Out of Specification MAP for ALL or DLBCL Patients

N/AAvailable

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space